Industry News

Biotechnology Industry News

A pair of Sage veterans has…

April 21st, 2026|FierceBiotech|

A pair of Sage veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage pipeline of assets licensed from Eisai and Hansoh.

Gene therapy biotech Ray…

April 21st, 2026|FierceBiotech|

Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s vision restoration candidates for patients with retinal degeneration.

Gilead and Arcus’ domvanalimab,…

April 21st, 2026|FierceBiotech|

Gilead and Arcus' domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging collaboration.

Since its 2014 founding, Zai Lab…

April 20th, 2026|FierceBiotech|

Since its 2014 founding, Zai Lab has built its business by licensing drugs from Big Pharma. But in the last three years, the company has sought to leverage its footholds in China and the U.S.

Eli Lilly is picking up its second…

April 20th, 2026|FierceBiotech|

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy.

Following its move to secure…

April 20th, 2026|FierceBiotech|

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biopharma.

Novo Nordisk is gearing up to…

April 20th, 2026|FierceBiotech|

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset reduced a painful complication of sickle cell disease (SCD) in a phase 3 study.

A phase 2 trial combining…

April 20th, 2026|FierceBiotech|

A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the study generating early evidence the cocktail improves survival, the biotechs said the data support further assessment

President Donald Trump has ordered…

April 20th, 2026|FierceBiotech|

President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear barriers to access to treatments for serious mental illnesses.

After dropping headline-grabbing…

April 18th, 2026|FierceBiotech|

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, Revolution Medicines is not resting on its laurels. The Bay Area biotech spent several recent days in San Diego highlighting earlier

The agreement fulfills several…

April 17th, 2026|FierceBiotech|

The agreement fulfills several ambitions for UCB. Besides building its epilepsy position, it "marks a strategic expansion into regenerative medicine and advanced therapies," the Belgian biopharma explained.

More than a year after licensing…

April 17th, 2026|FierceBiotech|

More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts similar safety and efficacy in non-small cell

Following its recently announced…

April 17th, 2026|FierceBiotech|

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to support research in biology, drug discovery and translational medicine.

Kailera Therapeutics appears to…

April 17th, 2026|FierceBiotech|

Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its pipeline of obesity therapies.

After helping guide Metsera…

April 16th, 2026|FierceBiotech|

After helping guide Metsera through its high-profile, $10 billion acquisition by Pfizer last year, Matthew Lang is swinging over to a different obesity biotech as chief operating officer and general counsel at Structure Therapeutics.

The traditional gold standard of…

April 16th, 2026|FierceBiotech|

The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients has inherently been unfeasible for the rare disease community.